Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry

A. De Soyza (Newcastle upon Tyne, United Kingdom), J. Chalmers (Dundee, United Kingdom), D. K (Athens, Greece), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), F. Blasi (Milano, Italy), F. Ringshausen (Hannover, Germany), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), W. Boersma (MCA.NL, Netherlands), A. Torres (Bacelona, Republic of Korea), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), C. Haworth (Cambs, United Kingdom), M. Murris (Toulouse, France), E. Polverino (Barcelona, Spain), S. Aliberti (Milano, Italy)

Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Session: Improving the quality of life of patients with bronchiectasis
Session type: Thematic Poster
Number: 2678
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. De Soyza (Newcastle upon Tyne, United Kingdom), J. Chalmers (Dundee, United Kingdom), D. K (Athens, Greece), A. Hill (Edinburgh, United Kingdom), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), F. Blasi (Milano, Italy), F. Ringshausen (Hannover, Germany), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), W. Boersma (MCA.NL, Netherlands), A. Torres (Bacelona, Republic of Korea), T. Welte (Hannover, Germany), R. Wilson (London, United Kingdom), C. Haworth (Cambs, United Kingdom), M. Murris (Toulouse, France), E. Polverino (Barcelona, Spain), S. Aliberti (Milano, Italy). Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry. 2678

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inflammatory bowel diseases in COPD patients.
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020

Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013

Rheumatoid arthritis and comorbid chronic obstructive or interstitial pulmonary diseases: Prevalence in a population-based cohort
Source: International Congress 2016 – Burden of respiratory diseases: from environmental aspects to healthcare consumption
Year: 2016

Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: Analysis of Medicare data
Source: International Congress 2016 – Burden of respiratory diseases: from environmental aspects to healthcare consumption
Year: 2016


Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021



Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients?
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014

Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014


Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry
Source: International Congress 2016 – IPF clinical
Year: 2016

Rheumatoid arthritis is a common and important comorbidity in bronchiectasis: Data from the EMBARC European bronchiectasis registry
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016

Inflammatory bowel diseases and the lung
Source: Eur Respir J 2006; 28: Suppl. 50, 55s
Year: 2006

Functional and inflammatory bowel diseases in patients with chronic obstructive pulmonary disease (COPD).
Source: International Congress 2019 – Advances in clinical management of COPD
Year: 2019

Does the HLA-DRB1-genotype influence the course of disease in Danish sarcoidosis patients?
Source: Annual Congress 2013 –Sarcoidosis
Year: 2013


PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014


Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014



Functional and inflammatory bowel diseases in patients with COPD
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017

The metabolic syndrome in patients with chronic obstructive pulmonary disease
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014


Health-related quality of life in idiopathic pulmonary fibrosis (IPF): First results based on the European IPF registry
Source: International Congress 2014 – ILDs 1
Year: 2014

Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018



Clinical presentation of chronic obstructive pulmonary disease (COPD): Study on-sint
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014


Late Breaking Abstract - Disease trajectories in GOLD B chronic obstructive pulmonary disease (COPD) patients  – nationwide data from Denmark
Source: Virtual Congress 2021 – COVID - 19, smoking and e-cigarettes
Year: 2021